Takeda Pharmaceuticals
Takeda (Osaka, Japan and Cambridge, MA based 240+ year old Global Pharmaceutical company with core therapeutics in gastrointestinal/inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines).
Retained Partner from 2021 – Present.
Involved with 2022 National Expansion Roles for Rare Disease Franchise.
Successfully placed 20+ Territory Business Managers for Plasma Derivative Therapies/Rare Disease/Neuromuscular Expansion. Primary focus is Neurology and Movement Disorders for (MMN) Multi Motor Neuropathy and upcoming indication HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] for the maintenance treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).